Condition
Hormone Sensitive Prostate Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Hormone Sensitive Prostate Cancer clinical trials that are recruiting, at sites in 26 countries (most in United States (2), Belgium (2), China (2)). By phase: Phase 3 (3), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 26Countries
Newest Hormone Sensitive Prostate Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve | Phase 3 | Huntsville, Alabama and 318 other locations | Recruiting | Jun 19, 2025 |
| Evaluating treatment outcomes for hormone-sensitive metastatic prostate cancer | — | Orbassano, Torino and 2 other locations | Recruiting | Jun 25, 2024 |
| Radiation therapy for recurrent prostate cancer | Phase 2 | Miami, Florida | Recruiting | Apr 30, 2024 |
| Comparing two treatments for metastatic hormone-sensitive prostate cancer | Phase 3 | Nanjing, Jiangsu | Recruiting | Aug 9, 2023 |
| Treatment for recurrent prostate cancer with metastases | Phase 3 | Leuven | Recruiting | Apr 28, 2022 |
All recruiting trials (5)
-
Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve
This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.
-
Evaluating treatment outcomes for hormone-sensitive metastatic prostate cancer
This study looks at how well different treatments work for men with hormone-sensitive metastatic prostate cancer who have just started hormone therapy.
-
Radiation therapy for recurrent prostate cancer
This study is testing a new way to use radiation therapy for men with recurrent prostate cancer to see if it helps control the cancer better while also keeping their quality of life intact.
-
Comparing two treatments for metastatic hormone-sensitive prostate cancer
This study is testing if adding chemotherapy to a hormone treatment can help men with advanced prostate cancer live longer compared to just using hormone treatment alone.
-
Treatment for recurrent prostate cancer with metastases
This study is testing whether combining hormone therapy with targeted radiation or surgery can help men with recurrent prostate cancer live longer without their cancer spreading.
Related topics
Quick answers
How many Hormone Sensitive Prostate Cancer clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 26 countries. The most sites are in United States (2 trials), Belgium (2 trials), China (2 trials), Italy (2 trials), Argentina (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.